Literature DB >> 17328661

High levels of primary antiretroviral resistance genotypic mutations and B/F recombinants in Santos, Brazil.

Maria Cecilia Araripe Sucupira1, Marcos Montani Caseiro, Katia Alves, Graziela Tescarollo, Luiz Mario Janini, Ester Cerdeira Sabino, Adauto Castelo, Kim Page-Shafer, Ricardo Sobhie Diaz.   

Abstract

This study characterized HIV-1 among antiretroviral-naïve populations presenting recent infection (RI) or long-standing infection (LSI). Sera collected from January 1999 to December 2001 at an anonymous HIV testing site in Santos, Brazil, were submitted to serologic testing algorithm for recent HIV seroconversion (STARHS). The STARHS methodology uses a combination of a sensitive and a less sensitive version of an anti-HIV enzyme immunoassay (EIA), and specimens found to be positive on the sensitive EIA and negative on the less sensitive EIA are considered to represent RI. HIV-1 V3 and pol regions of those with RI and LSI were compared. Antiretroviral resistance was defined solely by genotypic analysis. Ninety samples were evaluated representing those taken from an original cohort of 345 individuals, for whom adequate samples were available. Of 90 HIV-positive individuals, 25 presented RI. Cumulatively, 36.8% of those with RI and 25% of those with LSI presented resistance to at least one antiretroviral class. In the pol and V3 regions, 47% and 53% of those with RI presented clade B viruses and B/F recombinant viruses, respectively, whereas 56.2%, 41.7%, and 2.1% of those with LSI harbored clades B, B/F, and clade C viruses, respectively. Primary resistance and the prevalence of B/F recombinants was high in this population. Monitoring HIV-1 genetic diversity is important for developing vaccines and treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17328661     DOI: 10.1089/apc.2006.0079

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  15 in total

1.  Differential persistence of transmitted HIV-1 drug resistance mutation classes.

Authors:  Vivek Jain; Maria C Sucupira; Peter Bacchetti; Wendy Hartogensis; Ricardo S Diaz; Esper G Kallas; Luiz M Janini; Teri Liegler; Christopher D Pilcher; Robert M Grant; Rodrigo Cortes; Steven G Deeks; Frederick M Hecht
Journal:  J Infect Dis       Date:  2011-04-15       Impact factor: 5.226

2.  Enhanced detection of viral diversity using partial and near full-length genomes of human immunodeficiency virus Type 1 provirus deep sequencing data from recently infected donors at four blood centers in Brazil.

Authors:  Rodrigo Pessôa; Jaqueline Tomoko Watanabe; Paula Calabria; Cecilia Salete Alencar; Paula Loureiro; Maria Esther Lopes; Anna Barbara Proetti; Alvina Clara Félix; Ester C Sabino; Michael P Busch; Sabri S Sanabani
Journal:  Transfusion       Date:  2014-11-21       Impact factor: 3.157

3.  HIV genotypes and primary drug resistance among HIV-seropositive blood donors in Brazil: role of infected blood donors as sentinel populations for molecular surveillance of HIV.

Authors:  Cecília S Alencar; Ester C Sabino; Silvia M F Carvalho; Silvana C Leao; Anna B Carneiro-Proietti; Ligia Capuani; Cláudia L Oliveira; Danielle Carrick; Rebecca J Birch; Thelma T Gonçalez; Sheila Keating; Priscilla A Swanson; John Hackett; Michael P Busch
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07-01       Impact factor: 3.731

4.  Trends in prevalence of HIV-1 drug resistance in Thailand 2009-2010.

Authors:  Sayompoo Sanguansittianant; Nattakarn Nooroon; Poonlaph Phaengchomduan; Palanee Ammaranond
Journal:  J Clin Lab Anal       Date:  2013-09       Impact factor: 2.352

5.  Clinical, epidemiological and molecular features of the HIV-1 subtype C and recombinant forms that are circulating in the city of São Paulo, Brazil.

Authors:  Rosana Alcalde; Monick L Guimarães; Alberto J S Duarte; Jorge Casseb
Journal:  Virol J       Date:  2012-08-09       Impact factor: 4.099

6.  Faster HIV-1 disease progression among Brazilian individuals recently infected with CXCR4-utilizing strains.

Authors:  Maria Cecilia Araripe Sucupira; Sabri Sanabani; Rodrigo M Cortes; Maria Teresa M Giret; Helena Tomiyama; Mariana M Sauer; Ester Cerdeira Sabino; Luiz Mario Janini; Esper Georges Kallas; Ricardo Sobhie Diaz
Journal:  PLoS One       Date:  2012-01-26       Impact factor: 3.240

Review 7.  Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis.

Authors:  Santiago Avila-Rios; Omar Sued; Soo-Yon Rhee; Robert W Shafer; Gustavo Reyes-Teran; Giovanni Ravasi
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

8.  Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV.

Authors:  Lilian A Inocencio; Anderson A Pereira; Maria Cecilia A Sucupira; José Carlos C Fernandez; Célia P Jorge; Denise Fc Souza; Helena T Fink; Ricardo S Diaz; Irina M Becker; Theodoro A Suffert; Monica B Arruda; Olinda Macedo; Mariangela Bg Simão; Amilcar Tanuri
Journal:  J Int AIDS Soc       Date:  2009-09-18       Impact factor: 5.396

9.  Elevated risk for HIV-1 infection in adolescents and young adults in São Paulo, Brazil.

Authors:  Katia Cristina Bassichetto; Denise Pimentel Bergamaschi; Solange Maria Oliveira; Marylei Casteldelli Verri Deienno; Reginaldo Bortolato; Heloíza Vilma de Rezende; Thaís Arthur; Helena Tomiyama; Colyn Watkins; Fabio Mesquita; Maria Cristina Abbate; Esper Georges Kallas
Journal:  PLoS One       Date:  2008-01-09       Impact factor: 3.240

10.  Prevalence of transmitted HIV-1 antiretroviral resistance among patients initiating antiretroviral therapy in Brazil: a surveillance study using dried blood spots.

Authors:  Celina M P de Moraes Soares; Tania R C Vergara; Carlos Brites; Jose D U Brito; Gorki Grinberg; Marcos M Caseiro; Carlos Correa; Theodoro A Suffert; Flavio R Pereira; Michelle Camargo; Luiz M Janini; Shirley Komninakis; Maria C A Sucupira; Ricardo S Diaz
Journal:  J Int AIDS Soc       Date:  2014-09-22       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.